Clinical trials: sponsored by Henan Cancer Hospital
Non Small Cell Lung Cancer
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
Observe the efficacy and safety of sunvozertinib in the real world in the treatment of EGFRm aNSCLC patients with previous EGFR-TKI treatment
- Trial name
- NCT06786208
- Testing
- Sunvozertinib
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Henan Cancer Hospital
Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for…
- Trial name
- NCT06774222
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Henan Cancer Hospital
Unresectable Biliary Tract Carcinoma
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
This study is designed to combine anti-angiogenic drugs on the basis of PD-L1+ gemcitabine/cisplatin, hoping to further improve the curative effect of advanced BTC treatment and provide more choices for first-line treatment of…
- Trial name
- NCT06749730
- Testing
- Adebrelimab, Apatinib, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, HER2-positive Breast Cancer
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before…
- Trial name
- NCT06276868
- Testing
- Dalcilib+letrozole+HP treatment group
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Henan Cancer Hospital
Sentinel Lymph Node Biopsy
Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer
SLNB has been recommended by domestic and foreign guidelines for patients with initial cN1 and NAC descending to ycN0. However, the best technical path is still not very clear at present, and the long-term tumor safety data is…
- Trial name
- NCT06518135
- Testing
- SLNB group
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Henan Cancer Hospital
Metastatic Breast Cancer
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative…
- Trial name
- NCT05176080
- Testing
- Famitinib, SHR6390, Fulvestrant
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Hematologic Malignancies
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the…
- Trial name
- NCT05923541
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma (HCC)
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Indication: Hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) stage C. Study Objectives: This study aims to use a prospective single-center single-arm pilot approach to preliminarily obtain data on…
- Trial name
- NCT06685354
- Testing
- hepatic arterial infusion of recombinant human type 5 adenovirus
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Henan Cancer Hospital
HER2 Low Breast Carcinoma
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
HR-positive breast cancers accounts for about 50% to 60% of all breast cancer patients. Neoadjuvant Chemotherapy is the core treatment mode for this type of breast cancer, and endocrine therapy can be used in some low-risk…
- Trial name
- NCT05911958
- Testing
- SHR-A1811 for injection
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Breast cancer (BC) is one of most prevalent malignant tumors in the world. According to the 2020 edition of the global cancer statistics report, the incidence rate of BC has overtaken lung cancer to become the most commonly…
- Trial name
- NCT05063136
- Testing
- Capecitabine+endocrine therapy
- Where
- China
- Volunteers
- 1,979 people
- Sponsor
- Henan Cancer Hospital
Chemotherapy-induced Nausea and Vomiting
Anti-emetic Prophylaxis With or Without Dexamethasone
To evaluate the efficacy and safety of a fosaprepitant, tropisetron, and olanzapine antiemetic regimen, with or without dexamethasone, in patients receiving highly emetogenic chemotherapy with epirubicin and cyclophosphamide.
- Trial name
- NCT05242874
- Testing
- Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
- Where
- 2 sites in China
- Volunteers
- 442 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal…
- Trial name
- NCT05495152
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer
Local Injection and Systemic Therapy in the Treatment of NSCLC.
This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection…
- Trial name
- NCT06618391
- Testing
- Envafolimab, Recombinant human endostatin, recombinant human adenovirus type 5
- Volunteers
- 84 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer,HER2-positive
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
The aim of this study is to evaluates the efficacy of weekly nab-paclitaxel monotherapy compared to the standard regimen of docetaxel plus carboplatin, both supplemented with trastuzumab and pertuzumab, as neoadjuvant therapies…
- Trial name
- NCT04547907
- Testing
- Nab-paclitaxel+ trastuzumab+ patuzumab, Docetaxel+ carboplatin+ trastuzumab + patuzumab
- Where
- China
- Volunteers
- 688 people
- Sponsor
- Henan Cancer Hospital
Triple Negative Breast Cancer
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC
Previous studies have shown that TNBC is sensitive to DNA crosslinking-related chemotherapeutic drugs such as platinum. However, there is a lack of large sample prospective clinical data to compare the efficacy of TP and EC-T /…
- Trial name
- NCT04664972
- Testing
- Docetaxel +doxorubicin+ cyclophosphamide, Docetaxel +Cisplatin
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Henan Cancer Hospital
Locally Advanced Breast Cancer
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
For newly diagnosed ISLNM breast cancer, on the basis of effective treatment of the new auxiliary system, the optimal local treatment of the supraclavicular region remains controversial.
- Trial name
- NCT06605521
- Testing
- Subclavian lymph node dissection+radiotherapy, Simple clavicular region radiotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Henan Cancer Hospital
Extensive-stage Small-cell Lung Cancer
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
This is an open-label, single arm Phase II study designed to observe and evaluate the efficacy and safety of sequential thoracic radiotherapy in the first-line treatment of extensive small cell lung cancer with chemotherapy…
- Trial name
- NCT06586697
- Testing
- Thoracic Radiotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Advanced Breast Cancer, Treatment
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new…
- Conditions
- Advanced Breast Cancer, Treatment, HR Low/HER2 Negative
- Trial name
- NCT06176534
- Testing
- Experimental: chemotheyapy, Active Comparator: endocrine therapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Henan Cancer Hospital
Laryngeal Cancer, Hypopharynx Cancer
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of "tislelizumab combined with chemotherapy followed by…
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- NCT06554028
- Testing
- chemotherapy TP regimen combined with Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
KRAS G12V, T Cell Therapy
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
At present, there is an urgent need for new drugs for kirsten rat sarcoma viral oncogene (KRAS) mutant tumors in clinic. Preclinical studies support the specificity, safety and anti-tumor activity of RE001.
- Trial name
- NCT06545201
- Testing
- RE001 T cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital